Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Radiosensitizing drugs: lessons to be learned from the oxaliplatin story.

Flatmark K, Ree AH.

J Clin Oncol. 2010 Oct 10;28(29):e577-8; author reply e581-3. doi: 10.1200/JCO.2010.30.0921. Epub 2010 Aug 23. No abstract available.

2.

Are we ready to use an early alternative end point as the primary end point of a phase III study in rectal cancer?

Glynne-Jones R, Sebag-Montefiore D.

J Clin Oncol. 2010 Oct 10;28(29):e579-80; author reply e581-3. doi: 10.1200/JCO.2010.30.2067. Epub 2010 Aug 23. No abstract available.

3.
4.

[Chemotherapy and rectal cancer].

Michel P, Di Fiore F.

Cancer Radiother. 2011 Oct;15(6-7):436-9. doi: 10.1016/j.canrad.2011.06.002. Epub 2011 Aug 31. Review. French.

PMID:
21885319
5.

Combined modality treatment for rectal cancer.

Zhu AX, Willett CG.

Semin Oncol. 2005 Feb;32(1):103-12. Review.

PMID:
15726512
6.

Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.

Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W, Sauer R.

J Clin Oncol. 2007 Jan 1;25(1):110-7. Erratum in: J Clin Oncol. 2007 May 20;25(15):2149.

7.

Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?

Fakih MG.

Ann Oncol. 2006 Jun;17(6):1029-30; author reply 1030-1. Epub 2005 Dec 29. No abstract available.

8.

Preoperative sequential short-term radiotherapy plus chemotherapy can induce complete remission in T3N2 rectal cancer.

Widder J, Herbst F, Scheithauer W.

Acta Oncol. 2005;44(8):921-3. No abstract available.

PMID:
16332603
9.

Combined cetuximab, capecitabine, oxaliplatin, and radiotherapy in rectal cancer: Dr. Jekyll or Mr. Hyde? In regard to Rödel et al. (Int J Radiat Oncol Biol Phys 2008;70:1081-1086.).

Azria D.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):959-60; author reply 960. doi: 10.1016/j.ijrobp.2008.02.027. No abstract available.

PMID:
18514789
10.

Integration of novel agents into combined-modality treatment for rectal cancer patients.

Rödel C, Sauer R.

Strahlenther Onkol. 2007 May;183(5):227-35. Review.

PMID:
17497093
11.

Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer.

Aschele C, Lonardi S.

J Clin Oncol. 2007 Feb 10;25(5):602-3; author reply 603. No abstract available.

12.

Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.

Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C, Toepfer M.

Br J Cancer. 2008 Apr 8;98(7):1204-9. doi: 10.1038/sj.bjc.6604297. Epub 2008 Mar 18.

13.

[Laparoscopic ovarian transposition and cryopreservation of ovarian tissue before chemo-radiotherapy for rectal cancer].

Baron M, Resch B, Di Fiore F, Tenière P, Rives N.

Gynecol Obstet Fertil. 2007 Sep;35(9):772-5. Epub 2007 Aug 10. French.

PMID:
17693116
14.

Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.

Sastre J, Custodio A, Sanchez JC, Ortega L, Rodriguez L, Puente J, Corona J, Alfonso R, de las Heras M, Dıaz-Rubio E.

Anticancer Drugs. 2011 Feb;22(2):185-90.

PMID:
21218606
15.

Combined-modality therapy for rectal cancer: future prospects.

Czito BG, Willett CG, Bendell JC.

Clin Colorectal Cancer. 2007 Sep;6(9):625-33. Review.

PMID:
17945034
16.

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T.

J Clin Oncol. 2010 Apr 1;28(10):1638-44. doi: 10.1200/JCO.2009.25.8376. Epub 2010 Mar 1.

17.

Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.

Machiels JP, Duck L, Honhon B, Coster B, Coche JC, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, Canon JL, Van Maele P, Gilbeau L, Laurent S, Kirkove C, Octave-Prignot M, Baurain JF, Kartheuser A, Sempoux C.

Ann Oncol. 2005 Dec;16(12):1898-905. Epub 2005 Oct 11.

18.

Role of neoadjuvant treatment in cT3N0M0 rectal cancer.

Pasetto LM, Friso ML, Pucciarelli S, Basso U, Rugge M, Sinigaglia G, Rossi E, Compostella A, Toppan P, Agostini M, Monfardini S.

Anticancer Res. 2008 Nov-Dec;28(6B):4129-35.

19.

Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.

Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI.

Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8.

PMID:
17498568
20.

Current options for the management of rectal cancer.

O'Neil BH, Tepper JE.

Curr Treat Options Oncol. 2007 Oct;8(5):331-8. doi: 10.1007/s11864-007-0048-7. Review.

PMID:
18181024
Items per page

Supplemental Content

Write to the Help Desk